Published in Cancer Biol Ther on October 01, 2010
Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol (2013) 1.23
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget (2013) 1.10
Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One (2012) 1.02
Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des (2011) 0.99
Structural insights into the transcription-independent apoptotic pathway of p53. BMB Rep (2014) 0.89
p53 abnormalities and potential therapeutic targeting in multiple myeloma. Biomed Res Int (2014) 0.85
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol (2012) 0.85
Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy. Curr Pharm Des (2013) 0.84
Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Res (2015) 0.82
Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget (2016) 0.80
c-Abl mediates angiotensin II-induced apoptosis in podocytes. J Mol Histol (2013) 0.79
Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. Br J Cancer (2014) 0.79
The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery. Am J Blood Res (2011) 0.79
Nutlin's two roads toward apoptosis. Cancer Biol Ther (2010) 0.76
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. Int J Mol Sci (2016) 0.76
Identification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma. Oncotarget (2016) 0.75
Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res (2016) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
Surfing the p53 network. Nature (2000) 35.36
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
The DNA damage response: putting checkpoints in perspective. Nature (2000) 19.07
lumi: a pipeline for processing Illumina microarray. Bioinformatics (2008) 17.19
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 14.90
Multiple myeloma. N Engl J Med (2004) 10.81
The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene (2007) 10.08
Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science (2004) 9.52
p53 has a direct apoptogenic role at the mitochondria. Mol Cell (2003) 8.98
Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans (2006) 7.69
Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol (2004) 5.56
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A (2006) 4.68
Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem (2001) 4.21
Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem (2000) 4.11
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol (2009) 3.47
Functions of the MDM2 oncoprotein. Cell Mol Life Sci (1999) 3.35
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene (2002) 3.12
Defying death after DNA damage. Nature (2000) 3.03
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood (2005) 2.88
MDM2, an introduction. Mol Cancer Res (2003) 2.87
Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res (2003) 2.49
Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem (2004) 2.46
Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol (2005) 2.12
Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res (2008) 2.04
The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle (2009) 2.00
Multiple roles of the tumor suppressor p53. Curr Opin Oncol (2002) 1.99
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood (2008) 1.72
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood (2006) 1.71
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood (2005) 1.69
Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem (2005) 1.67
Clinical significance of TP53 mutation in myeloma. Leukemia (2007) 1.62
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood (2006) 1.49
Transcription, apoptosis and p53: catch-22. Trends Genet (2005) 1.39
MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia (2008) 1.36
Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res (2007) 1.18
Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia (2005) 1.16
Pharmacological activation of the p53 pathway in haematological malignancies. J Clin Pathol (2009) 1.15
MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther (2010) 1.14
p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog (2006) 1.12
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res (2009) 1.09
Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma. Br J Haematol (2007) 1.00
The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53. Leukemia (2009) 0.89
Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther (2007) 0.83
Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc. Int J Cancer (2010) 0.80
Cross-leg flaps: our preferred alternative to free flaps in the treatment of complex traumatic lower extremity wounds. J Am Coll Surg (2013) 4.30
Measuring patients' experiences with individual primary care physicians. Results of a statewide demonstration project. J Gen Intern Med (2006) 4.17
Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood) (2006) 3.16
CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavorable acute myeloid leukemia. Leuk Res (2012) 2.60
Glacial-interglacial Indian summer monsoon dynamics. Science (2011) 2.31
Growing trend of China's contribution to the field of plastic and reconstructive surgery: a 10-year study of the literature. Ann Plast Surg (2012) 2.26
Physician-patient communication about prescription medication nonadherence: a 50-state study of America's seniors. J Gen Intern Med (2007) 2.15
Job performance deficits due to depression. Am J Psychiatry (2006) 2.09
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood (2009) 2.07
Evaluating patients' experiences with individual physicians: a randomized trial of mail, internet, and interactive voice response telephone administration of surveys. Med Care (2006) 2.07
Development of genome-wide DNA polymorphism database for map-based cloning of rice genes. Plant Physiol (2004) 1.98
Interplay between the Westerlies and Asian monsoon recorded in Lake Qinghai sediments since 32 ka. Sci Rep (2012) 1.95
Optical imaging of bacterial infection in living mice using a fluorescent near-infrared molecular probe. J Am Chem Soc (2006) 1.93
Genetic variants in GPR126 are associated with adolescent idiopathic scoliosis. Nat Genet (2013) 1.90
Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model. J Virol (2002) 1.87
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood (2004) 1.82
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 1.77
Primary care quality in the Medicare Program: comparing the performance of Medicare health maintenance organizations and traditional fee-for-service medicare. Arch Intern Med (2002) 1.74
Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma (2011) 1.70
Unemployment, job retention, and productivity loss among employees with depression. Psychiatr Serv (2004) 1.65
Template-induced screw motions within an aromatic amide foldamer double helix. Angew Chem Int Ed Engl (2011) 1.57
Cost-related skipping of medications and other treatments among Medicare beneficiaries between 1998 and 2000. Results of a national study. J Gen Intern Med (2005) 1.57
Lef1 is required for the transition of Wnt signaling from mesenchymal to epithelial cells in the mouse embryonic mammary gland. Dev Biol (2006) 1.55
Anterior cervical discectomy versus corpectomy for multilevel cervical spondylotic myelopathy: a meta-analysis. Eur Spine J (2014) 1.51
Relationship of employee-reported work limitations to work productivity. Med Care (2003) 1.51
CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology (2007) 1.49
Adult precursor T-lymphoblastic leukemia/lymphoma with myeloid-associated antigen expression is associated with a lower complete remission rate following induction chemotherapy. Acta Haematol (2008) 1.49
Primary care experiences of medicare beneficiaries, 1998 to 2000. J Gen Intern Med (2004) 1.47
Age-related change of postoperative pain location after Nuss procedure for pectus excavatum. Eur J Cardiothorac Surg (2010) 1.46
Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res (2004) 1.44
Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis. Int J Dermatol (2004) 1.42
Analysis of chromosome 12p deletion in plasma cell dyscrasias. Leuk Res (2011) 1.41
Relationship between all-cause mortality and cumulative working life course psychosocial and physical exposures in the United States labor market from 1968 to 1992. Psychosom Med (2002) 1.38
The clinical and occupational correlates of work productivity loss among employed patients with depression. J Occup Environ Med (2004) 1.38
Defective in Tapetal development and function 1 is essential for anther development and tapetal function for microspore maturation in Arabidopsis. Plant J (2008) 1.38
Affinity proteomics reveals human host factors implicated in discrete stages of LINE-1 retrotransposition. Cell (2013) 1.34
Noninvasive optical imaging of staphylococcus aureus bacterial infection in living mice using a Bis-dipicolylamine-Zinc(II) affinity group conjugated to a near-infrared fluorophore. Bioconjug Chem (2008) 1.34
Bipolar fractional radiofrequency treatment induces neoelastogenesis and neocollagenesis. Lasers Surg Med (2009) 1.32
TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice. J Invest Dermatol (2012) 1.29
Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol (2009) 1.28
Altered hepatic and muscle substrate utilization provoked by GLUT4 ablation. Diabetes (2005) 1.27
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica (2008) 1.27
Photoaging is associated with protein oxidation in human skin in vivo. J Invest Dermatol (2002) 1.25
Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol (2013) 1.23
Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol (2009) 1.22
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood (2006) 1.20
Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol (2004) 1.20
The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. Oncogene (2005) 1.18
Pharmacological activation of the p53 pathway in haematological malignancies. J Clin Pathol (2009) 1.15
Improved methodology for the affinity isolation of human protein complexes expressed at near endogenous levels. Biotechniques (2012) 1.15
MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther (2010) 1.14
Hydroxylated polybrominated diphenyl ethers and bisphenol A in pregnant women and their matching fetuses: placental transfer and potential risks. Environ Sci Technol (2010) 1.13
Double-bar application decreases postoperative pain after the Nuss procedure. J Thorac Cardiovasc Surg (2010) 1.13
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther (2007) 1.11
A novel method for metal oxide nanowire synthesis. Nanotechnology (2009) 1.11
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget (2013) 1.10
A kernel approach for semisupervised metric learning. IEEE Trans Neural Netw (2007) 1.10
Integrated stress response modulates cellular redox state via induction of cystathionine γ-lyase: cross-talk between integrated stress response and thiol metabolism. J Biol Chem (2012) 1.10
Living donor adult liver transplantation: a longitudinal study of the donor's quality of life. Am J Transplant (2005) 1.09
Screening for depressive disorders in patients with skin diseases: a comparison of three screeners. Acta Derm Venereol (2005) 1.09
Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas. Hum Pathol (2009) 1.08
Short-term external buckling with pneumatic retinopexy for retinal detachment with inferior retinal breaks. Am J Ophthalmol (2013) 1.08
Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5+ B cells. Immunology (2011) 1.08
Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. J Plast Reconstr Aesthet Surg (2007) 1.07
Temporal and parental-specific expression of imprinted genes in a newly derived Chinese human embryonic stem cell line and embryoid bodies. Hum Mol Genet (2005) 1.07
Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia (2011) 1.07
Polybrominated diphenyl ethers and their hydroxylated/methoxylated analogs: environmental sources, metabolic relationships, and relative toxicities. Mar Pollut Bull (2011) 1.06
Patient samples for measuring primary care physician performance: who should be included? Med Care (2007) 1.05
Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken) (2011) 1.04
Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Haematologica (2007) 1.04
An imprinted gene underlies postzygotic reproductive isolation in Arabidopsis thaliana. Dev Cell (2013) 1.04
Helix-rod host-guest complexes with shuttling rates much faster than disassembly. Science (2011) 1.04
Ptch1 is required locally for mammary gland morphogenesis and systemically for ductal elongation. Development (2009) 1.03
Cystathionine beta-synthase null homocystinuric mice fail to exhibit altered hemostasis or lowering of plasma homocysteine in response to betaine treatment. Mol Genet Metab (2010) 1.03
Comparison of microwave ablation and multipolar radiofrequency ablation in vivo using two internally cooled probes. AJR Am J Roentgenol (2012) 1.03
Two-dimensional topological insulator state and topological phase transition in bilayer graphene. Phys Rev Lett (2011) 1.02
Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One (2012) 1.02
Work performance of employees with depression: the impact of work stressors. Am J Health Promot (2010) 1.01
Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol (2011) 1.01
Measuring patients' experiences with individual specialist physicians and their practices. Am J Med Qual (2009) 1.01
Germline-competent mouse-induced pluripotent stem cell lines generated on human fibroblasts without exogenous leukemia inhibitory factor. PLoS One (2009) 1.01
Increased numbers of P63-positive/CD117-positive cells in advanced adenoid cystic carcinoma give a poorer prognosis. Diagn Pathol (2012) 1.00
Determination of penicillin G and its degradation products in a penicillin production wastewater treatment plant and the receiving river. Water Res (2007) 1.00
Bisphenol A disrupts steroidogenesis in human H295R cells. Toxicol Sci (2011) 1.00
Providing patients web-based data to inform physician choice: if you build it, will they come? J Gen Intern Med (2007) 1.00
Origin of hydroxylated brominated diphenyl ethers: natural compounds or man-made flame retardants? Environ Sci Technol (2009) 1.00
A novel transgenic mouse model of CBS-deficient homocystinuria does not incur hepatic steatosis or fibrosis and exhibits a hypercoagulative phenotype that is ameliorated by betaine treatment. Mol Genet Metab (2010) 1.00
Cystathionine protects against endoplasmic reticulum stress-induced lipid accumulation, tissue injury, and apoptotic cell death. J Biol Chem (2012) 1.00
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica (2011) 0.99
Chiral-selective growth of single-walled carbon nanotubes on lattice-mismatched epitaxial cobalt nanoparticles. Sci Rep (2013) 0.99
Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma. Cancer Lett (2009) 0.99
The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. Clin Cancer Res (2002) 0.99
Interfacial engineering by proteins: exfoliation and functionalization of graphene by hydrophobins. Angew Chem Int Ed Engl (2010) 0.99
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol (2005) 0.99
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res (2003) 0.98
Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats. Am J Respir Cell Mol Biol (2012) 0.98
PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol Cancer Ther (2013) 0.98